COX

Rehmapicrogenin is a selective inhibitor of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). This compound, derived from the root of Rehmannia glutinosa, demonstrates significant anti-inflammatory properties, making it a valuable tool for research focused on inflammation pathways. Its ability to inhibit pro-inflammatory mediators such as IL-6 further underscores its relevance in studies aimed at understanding and treating inflammatory diseases.

(S)-(+)-Ibuprofen-d3 is a deuterated analog of (S)-(+)-Ibuprofen, targeting the COX-1 and COX-2 enzymes. With IC50 values of 2.1 μM and 1.6 μM, respectively, this compound exhibits significant analgesic, anti-inflammatory, and antipyretic properties. It serves as a valuable tool for studying the pharmacodynamics and mechanisms of nonsteroidal anti-inflammatory drugs (NSAIDs) in various biological research applications.

Isoxicam is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Its primary mechanism involves the inhibition of prostaglandin synthesis, making it effective in reducing inflammation and pain. Isoxicam is commonly utilized in research related to arthritis and other inflammatory conditions, providing valuable insights into the role of COX enzymes in various biological processes.

Cimicoxib is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier. It displays significant anti-inflammatory, analgesic, and antipyretic properties by inhibiting the production of thromboxane B2 and prostaglandin E2, with an IC50 of 66 nM against human COX-2. Additionally, Cimicoxib targets CYP2D15, exhibiting an IC50 of 1.6 μM in canines and 0.056 μM in felines. This compound is utilized in research involving inflammatory diseases, osteoarthritis, and perioperative pain management in orthopedic and soft tissue surgeries.

Naproxen glucuronide, a metabolite of naproxen, functions as a non-selective cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory, analgesic, and antipyretic activity, making it useful in the study of pain relief and inflammation pathways. Research applications include examining its metabolic pathways, assessing its efficacy in various inflammatory conditions, and exploring its pharmacokinetic properties in biological systems.

ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts.

Apricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating a potent inhibitory effect on PGE2 production with an IC50 of 1.5 nM. This compound exhibits notable biological activities, including anticancer, analgesic, and anti-inflammatory properties. Apricoxib is a valuable tool for research applications focused on inflammation, pain management, and cancer therapeutics.

LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms.

1-Oxo Ibuprofen is a cyclooxygenase (COX) inhibitor, specifically targeting COX-1 and COX-2 enzymes. As a degradation product and potential impurity of Ibuprofen, it demonstrates significant anti-inflammatory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This compound is useful for research applications involving the study of prostaglandin synthesis and the metabolic pathways of nonsteroidal anti-inflammatory drugs.

10,12-Tricosadiynoic acid is a selective and potent inhibitor of acyl-CoA oxidase-1 (ACOX1). It demonstrates significant potential in addressing metabolic disorders induced by high-fat diets or obesity by enhancing mitochondrial lipid metabolism and modulating reactive oxygen species (ROS) levels. Additionally, this compound serves as a versatile click chemistry reagent, featuring an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it valuable for various biochemical applications.

FR122047 (hydrochloride) is a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 value of 28 nM. This compound exhibits antiplatelet, analgesic, and anti-inflammatory activities, making it a valuable tool for research in the fields of pain management and cardiovascular studies. Its ability to modulate COX-1 offers insights into the therapeutic targeting of inflammatory pathways.

Zaltoprofen is a non-steroidal anti-inflammatory drug (NSAID) that acts as a preferential inhibitor of cyclooxygenase-2 (COX-2), exhibiting IC50 values of 1.3 μM for COX-1 and 0.34 μM for COX-2. It demonstrates significant anti-inflammatory and analgesic properties, making it beneficial for the management of inflammatory pain. Zaltoprofen is utilized in research settings to explore mechanisms of inflammation and pain pathways.

6-Methoxy-2-naphthoic acid is a potent inhibitor of COX-1 and COX-2 enzymes. It effectively inhibits the synthesis of gastric mucosal prostaglandin E2, making it relevant in studies related to inflammation and pain-related conditions. Additionally, 6-Methoxy-2-naphthoic acid serves as an impurity in Naproxen and can be utilized in the synthesis of various active compounds, contributing to diverse research applications in pharmaceutical development.

Parecoxib Sodium is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier and serves as a proagent for Valdecoxib. This nonsteroidal anti-inflammatory drug (NSAID) inhibits prostaglandin synthesis, making it suitable for the relief of acute postoperative pain as well as for managing symptoms associated with chronic inflammatory conditions, including osteoarthritis and rheumatoid arthritis. It has important applications in both clinical and preclinical research focused on pain management and inflammation.

Tolmetin sodium dihydrate is a potent non-steroidal anti-inflammatory drug (NSAID) that primarily targets cyclooxygenase (COX) enzymes, exhibiting IC50 values of 0.35 μM for human COX-1 and 0.82 μM for COX-2. This compound is commonly utilized in research related to inflammation and pain modulation. Its ability to effectively inhibit COX activity makes it valuable for studying various inflammatory pathways and developing new therapeutic strategies in pain management.

Hamaudol is a chromone derived from Saposhnikovia divaricata, acting as a potent inhibitor of cyclooxygenase (COX)-1 and COX-2, with IC50 values of 0.30 mM and 0.57 mM, respectively. This compound exhibits significant analgesic and anti-inflammatory properties, making it a valuable tool in research focused on pain relief and inflammation modulation. Hamaudol is suitable for investigations into COX inhibition and related biological pathways.

Methylhydroquinone is a potent COX inhibitor with noted activity against ovine COX-1 and human recombinant COX-2, exhibiting IC50 values of 480.7 μM and 52.2 μM, respectively. This compound demonstrates anti-inflammatory properties primarily through the inhibition of prostaglandin synthesis. Additionally, it has been associated with potential DNA-damaging effects, including the induction of DNA single-strand breaks. Methylhydroquinone functions by competitively binding to the active sites of COX-1, engaging in non-covalent interactions to exert its biological activities.